272 related articles for article (PubMed ID: 23196276)
21. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
22. Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
Yamada M; Kudoh S; Fukuda H; Nakagawa K; Yamamoto N; Nishimura Y; Negoro S; Takeda K; Tanaka M; Fukuoka M
Br J Cancer; 2002 Jul; 87(3):258-63. PubMed ID: 12177791
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
Komaki R; Paulus R; Ettinger DS; Videtic GM; Bradley JD; Glisson BS; Langer CJ; Sause WT; Curran WJ; Choy H
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e531-6. PubMed ID: 22560543
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
Edelman MJ; Chansky K; Gaspar LE; Leigh B; Weiss GR; Taylor SA; Crowley J; Livingston R; Gandara DR
J Clin Oncol; 2004 Jan; 22(1):127-32. PubMed ID: 14701775
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.
Fukuda M; Soda H; Fukuda M; Kinoshita A; Nakamura Y; Nagashima S; Takatani H; Tsukamoto K; Kohno S; Oka M
Cancer; 2007 Aug; 110(3):606-13. PubMed ID: 17577234
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
Klautke G; Fähndrich S; Semrau S; Büscher C; Virchow C; Fietkau R
Lung Cancer; 2006 Aug; 53(2):183-8. PubMed ID: 16757061
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group.
Horn L; Bernardo P; Sandler A; Wagner H; Levitan N; Levitt ML; Johnson DH
J Thorac Oncol; 2009 Apr; 4(4):527-33. PubMed ID: 19240650
[TBL] [Abstract][Full Text] [Related]
28. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
30. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Owonikoko TK; Aisner J; Wang XV; Dahlberg SE; Rubin EH; Ramalingam SS; Gounder M; Rausch PG; Axelrod RS; Schiller JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):171-80. PubMed ID: 24288121
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
32. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
Ichinose Y; Seto T; Sasaki T; Yamanaka T; Okamoto I; Takeda K; Tanaka M; Katakami N; Sawa T; Kudoh S; Saka H; Nishimura Y; Nakagawa K; Fukuoka M
J Thorac Oncol; 2011 Dec; 6(12):2069-75. PubMed ID: 22052226
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
Glisson B; Scott C; Komaki R; Movsas B; Wagner H
J Clin Oncol; 2000 Aug; 18(16):2990-5. PubMed ID: 10944132
[TBL] [Abstract][Full Text] [Related]
34. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
[TBL] [Abstract][Full Text] [Related]
35. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
Miller AA; Case D; Atkins JN; Giguere JK; Bearden JD
J Thorac Oncol; 2006 Oct; 1(8):832-6. PubMed ID: 17409967
[TBL] [Abstract][Full Text] [Related]
37. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
[TBL] [Abstract][Full Text] [Related]
38. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Liew MS; Sia J; Starmans MH; Tafreshi A; Harris S; Feigen M; White S; Zimet A; Lambin P; Boutros PC; Mitchell P; John T
Cancer Med; 2013 Dec; 2(6):916-24. PubMed ID: 24403265
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.
Sohn JH; Moon YW; Lee CG; Kim GE; Chung KY; Chang J; Kim SK; Kim YS; Choi BW; Choi HJ; Kim JH
Cancer; 2007 May; 109(9):1845-950. PubMed ID: 17366589
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
